Compliance with Market Abuse Regulation

Summary by AI BETAClose X

The Biotech Growth Trust PLC confirms compliance with Market Abuse Regulation, stating that all inside information has been notified to a Regulated Information Service and that its net asset value per share is announced daily. The company has no reason to believe there will be a material difference between the net asset value per share as of September 30, 2026, announced on October 1, 2026, and the financial information to be published in its half-year results. Consequently, the company is permitted to deal in its own securities during the current closed period, which will conclude upon the release of its half-year results.

Disclaimer*

 

The Biotech Growth Trust PLC

(the "Company")

 

 

Compliance with Market Abuse Regulation

 

12 October 2026

 

The Company confirms that:

 

a) all inside information which the Directors and Company may have had has been notified to a Regulated Information Service ("RIS");

 

b) the Company's net asset value per share is calculated and announced through a RIS on a daily basis;

 

c) the Company has no reason to believe that there will be any material difference between the net asset value per share as at close of business on Wednesday, 30 September 2026, which was announced on Thursday, 1 October 2026, and the financial information to be published in the announcement of its results for the half year ended 30 September 2026.

 

The Company is, therefore, not prohibited from dealing in its own securities during the closed period, as defined by the UK Market Abuse Regulation, which will end on the date of the publication of its results for the half year ended 30 September 2026.

 

-ENDS-

For further information please contact:

Katherine Manson  Frostrow Capital LLP - 0203 709 8734

 




UK 100